SBMFF · Sino Biopharmaceutical Limited · Investor Relations
Market Cap
$11.83B
Shares
17.78B
Volume · Nov 11
300
Avg daily vol (10 sessions)
3840
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-11-09 | AASLD 2026 | 乙肝表面抗原清除率达20.8%!正大天晴TQ-A3334交出免疫治疗“新答卷” |
| 2026-11-03 | 上海生物医药企业国际化发展协会召开首届会员大会,谢其润当选会长 |
| 2026-11-03 | 谢其润出席WCE峰会:AI驱动全球医药创新,以开放生态汇聚“她力量” |
| 2026-10-30 | 承契致远,共拓新程!正大天晴赴复旦大学附属肿瘤医院开展战略回访交流 |
| 2026-10-27 | 乙肝治疗迎来创新浪潮!中国生物制药2款乙肝新药同日获突破性治疗认定 |
| 2026-10-26 | 1亿元战略合作!南京正大天晴携手中国科技发展基金会,打造产学研医协同新范式 |
| 2026-10-15 | 香港财政司司长陈茂波率队考察正大天晴,苏港携手共建全球出海新通道 |
| 2026-10-13 | 2026科技+新质生产力高峰论坛在港举行,郑翔玲:推动香港成为科技成果“超级落地人” |
| 2026-10-10 | 入选ESG标杆案例,中国生物制药“EAP员工关爱计划”获权威认可 |
| 2026-10-09 | 2026 IGCS丨中位PFS达27.43个月!安罗替尼一线治疗晚期卵巢癌公布最新临床数据 |
Source: https://www.sbpgroup.com/investor-relations/information-disclosure/